OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $255,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock in a transaction that occurred on Friday, March 28th. The stock was acquired at an average price of $1.70 per share, with a total value of $255,000.00. Following the transaction, the chief executive officer now owns 213,651,448 shares in the company, valued at $363,207,461.60. The trade was a 0.07 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Monday, March 17th, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The stock was purchased at an average cost of $1.74 per share, for a total transaction of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost bought 67,434 shares of OPKO Health stock. The stock was purchased at an average price of $1.71 per share, with a total value of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost purchased 47,537 shares of OPKO Health stock. The shares were purchased at an average cost of $1.47 per share, with a total value of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.47 per share, for a total transaction of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.48 per share, with a total value of $740,000.00.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.70 on Monday. The business has a 50 day moving average price of $1.68 and a 200 day moving average price of $1.58. The company has a market capitalization of $1.14 billion, a P/E ratio of -8.95 and a beta of 1.70. OPKO Health, Inc. has a 1-year low of $1.15 and a 1-year high of $2.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million during the quarter, compared to analysts’ expectations of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. Sell-side analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Analyst Ratings Changes

OPK has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Wednesday, March 19th. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Wednesday, March 12th.

Hedge Funds Weigh In On OPKO Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its position in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 12,417 shares during the last quarter. Orion Portfolio Solutions LLC purchased a new position in OPKO Health during the third quarter worth $45,000. Cibc World Markets Corp acquired a new position in shares of OPKO Health in the fourth quarter worth $45,000. Finally, Zacks Investment Management purchased a new stake in shares of OPKO Health in the fourth quarter valued at $49,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.